Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Pharmacokinetics of Single-ascending Doses of RCS-21 in Healthy Volunteers. A Double Blind, Randomized, Placebo Controlled Phase I Study.

NCT06752122 is registered in ClinicalTrials.gov with RNATICS GmbH as lead sponsor.

NCT NCT06752122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Pharmacokinetics of Single-ascending Doses of RCS-21 in Healthy Volunteers. A Double Blind, Randomized, Placebo Controlled Phase I Study.
Lead sponsor
RNATICS GmbH
Phase
Phase 1
Overall status
Recruiting
Start date
February 18, 2025
Completion date
August 31, 2026
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, pharmacokinetics, safety, tolerability